Biotech stocks are back in favor thanks to two recent major developments that led to a rally in the sector. The first catalyst was Gilead Sciences’ (GILD - Free Report) announcement that it will be acquiring immunotherapy focused company, Kite Pharma while the FDA approval of the first gene therapy in the United States, Novartis AG’s Kymriah, boosted the sector further.
The Gilead-Kite deal has raised expectations that the sector will finally see more merger and acquisition (M&A) deals in the coming quarters. Moreover, companies involved in CAR-T treatment like Kite saw their shares shooting up on hopes that more M&A deals will be announced in this segment of the market.
Meanwhile, the approval of Novartis’ CAR-T therapy, Kymriah, also gave the sector a boost indicating the beginning of a new era in the treatment of cancer. The path-breaking immunocellular therapy is a one-time treatment that uses a patient's own T cells to fight cancer.
Year to date, the Nasdaq Biotechnology Index is up an impressive 26.1%, representing a sharp contrast to the Index’s performance during this same time period last year when it recorded a decline of 18.2%.
A key reason for last year’s dismal performance was the drug pricing controversy which weighed on the sector a major part of the year. However, investors now seem to be more comfortable with the drug pricing scenario and are willing to look at the fundamentals of the sector.
A key question that remains on the minds of investors is whether the rally will continue and what are the factors that will drive the same.
Firstly, this is an industry that will continue to witness demand for its products given an aging population and the increasing prevalence of a wide variety of diseases. Strong pipelines, innovative treatments, impressive results, and increased health care spending should support growth. Trump's pro-business stand is also expected to benefit the sector.
A faster drug approval process and the proposed removal of outdated regulations that drive up costs and slow down innovation should also work in favor of the sector. The FDA has approved far more drugs so far in 2017 than it did in the whole of 2016. The sector will receive an additional boost if more M&A deals are announced though companies are likely to adopt a “wait and watch” stance as they await more clarity regarding the drug pricing situation and tax reforms. Another major deterrent could be high valuations with companies remaining wary of bidding wars leading to over-priced deals.
That said, licensing deals should continue especially in orphan and rare disease areas as well as highly sought after therapeutic areas like immune-oncology.
Picking the Right Stocks
Picking biotech stocks can be a bit tricky given the “high risk - high returns” nature of the industry. Moreover, the estimate revision trend for the sector is not very encouraging. The growing presence of biosimilars, a slowdown in growth of legacy products and high profile pipeline setbacks are also challenges for the sector.
Keeping these factors in mind, we have zeroed in on five biotech stocks that currently hold a strong Zacks Rank and look well-positioned.
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) : Tarrytown, NY-based Regeneron's key areas of focus include eye diseases, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases. While eye drug, Eylea, the company’s key growth driver continues to perform well, Regeneron has been working on diversifying its portfolio and gained FDA approval for two drugs this year - Dupixent (moderate-to-severe atopic dermatitis) and Kevzara (moderately to severely active rheumatoid arthritis). Both drugs have blockbuster potential.
The company also has a strong pipeline and has an eventful second half of the year coming up with key mid-to-late stage pipeline catalysts lined up. Regeneron just reported positive top-line phase III data on Dupixent for asthma and is now looking to go ahead with a U.S. filing by year end. Dupixent should also gain EU approval for the eczema indication in the third quarter. Regeneron is evaluating Dupixent in the pediatric atopic dermatitis setting. Another important data readout scheduled for the second half of the year is on the company’s PD-1 antibody REGN2810, for cutaneous squamous cell carcinoma ("CSCC"), the second most common skin cancer after basal cell carcinoma and the second deadliest skin cancer after melanoma. Positive data would allow the company to file for FDA approval in the first quarter of 2018.
Meanwhile, Eylea is being evaluated in combination with nesvacumab. Top-line data from two phase II studies - one in wet age-related macular degeneration and another in diabetic macular edema - are expected in the fourth quarter of the year.
Regeneron, a Zacks Rank #1 (Strong Buy) stock, has gained 28.4% year to date, substantially outperforming the 15.6% rally of the industry it belongs to.
Alexion Pharmaceuticals, Inc. (ALXN - Free Report) : New Haven, CT-based Alexion’s flagship product, Soliris (eculizumab), continues to perform well and the company is working on expanding Soliris’ label for additional indications. Alexion has a key catalyst coming up with a decision from the FDA expected by Oct 23, 2017, regarding the approvability of Soliris for refractory generalized myasthenia gravis (gMG). EU approval for this indication came last month making it the first and only complement-based therapy approved for an ultra-rare subset of gMG. The gMG indication represents incremental growth opportunity for Soliris.
Alexion, which had a rough 2016 with shares falling 35.9%, looks set to recover lost ground with shares gaining 15.4% year to date. The efforts of the company’s new management team to turn things around are impressive. Alexion’s R&D strategy is being redefined with a focus on key expertise areas. The company will continue to grow its rare diseases business which includes Soliris, Strensiq and Kanuma. To increase productivity, Alexion will focus its internal research efforts on its complement expertise and its development efforts on its core therapeutic areas of hematology, nephrology, neurology and metabolic disorders. The company has also decided to de-prioritize certain pipeline candidates and is discontinuing its preclinical programs with mRNA therapies as well as other preclinical programs that do not fall within the complement franchise. Alexion is a Zacks Rank #1 stock. You can see the complete list of today’s Zacks #1 Rank stocks here.
Ligand Pharmaceuticals Incorporated (LGND - Free Report) : San Diego, CA-based Ligand’s business model is based on developing or acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. The company is focused on the development and licensing of biopharmaceutical assets. Ligand’s Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Ligand’s partners include big names like Amgen and Novartis among others. The company also has licensing deals based on its OmniAb technology. Ligand, a Zacks Rank #1 stock, has gained 34.5% year to date, substantially outperforming the 15.7% rally of the industry it belongs to.
Sangamo Therapeutics (SGMO - Free Report) : Richmond, CA-based Sangamo is focused on translating ground-breaking science into genomic therapies using its platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo got a major boost earlier this year following the signing of a collaboration agreement with Pfizer for the development and commercialization of gene therapy programs for hemophilia A.
Shares of Sangamo, a Zacks Rank #2 (Buy) stock, have gained 341% year to date, significantly outperforming the industry’s 15.7% rally.
Fate Therapeutics, Inc. (FATE - Free Report) : San Diego, CA-based Fate is focused on the development of programmed cellular immunotherapies for cancer and immune disorders. Fate’s hematopoietic cell therapy pipeline includes NK- and T-cell immuno-oncology programs and immuno-regulatory programs. Shares of Fate, a Zacks Rank #2 stock, have gained 64.1% year to date, significantly outperforming the industry’s 15.7% rally.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>